Lessons Learned From Major Clinical Outcomes Trials Involving Sodium-Glucose Cotransporter 2 Inhibitors.
Wojeck BS, Inzucchi SE. Lessons Learned From Major Clinical Outcomes Trials Involving Sodium-Glucose Cotransporter 2 Inhibitors. Diabetes Spectrum 2021, 34: 235-242. PMID: 34511849, PMCID: PMC8387615, DOI: 10.2337/ds20-0070.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSodium-glucose cotransporter 2 inhibitorsCotransporter 2 inhibitorsMajor clinical outcome trialsRecent large clinical trialsDiabetes treatment guidelinesGlucose-lowering medicationsChronic kidney diseaseClinical outcome trialsLarge clinical trialsRenal outcomesOutcome trialsTreatment guidelinesKidney diseaseRisk factorsClinical trialsMedicationsTrialsInhibitorsDiabetesDiseaseResponse to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015
Neeland IJ, Kasai T, Inzucchi SE, Wojeck BS, Yaggi HK, Johansen OE. Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015. Diabetes Care 2021, 44: e137-e138. PMID: 34016610, PMCID: PMC8247494, DOI: 10.2337/dci21-0009.Commentaries, Editorials and Letters